REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of ...

In type 1 diabetes, the body’s own immune system turns against the pancreas. Cells meant to protect you start destroying ...

You’ve worked extensively on respiratory syncytial virus (RSV) and influenza. What are the key differences in how the immune ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

Researchers identified a natural 'brake' within the innate immune system: the inhibitory receptor Siglec-E (SigE) and its human counterparts, Siglec-7 and Siglec-9. This receptor helps prevent ...

Current treatments to prevent organ transplant rejection focus mainly on suppressing T cells, part of the adaptive immune ...

Comb jellies "could repurpose [their] genetic toolkit in different ways like a Swiss knife," said the researchers.

Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE ...

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

Let us delve into some of the TLR agonists in the clinic and why the careful selection of these drugs is crucial.

USask researchers recently published a paper in Scientific Reports that identified a promising alternative for controlling ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...